FOLH1 and posterior cortical atrophy: The authors suggested that [99mTc]Tc-PSMA-T4 could be used for the diagnosis of recurrent disease to determine the personalization of treatment in patients with PCa and biochemical progression if PSA is higher than 0.5 ng/mL [151].